COSMIC-021: Cabozantinib + atezolizumab gives clinical activity in inoperable metastatic UC

ASCO 2022: Efficacy of Cabozantinib + Atezolizumab to Treat Urothelial CarcinomaПодробнее

Cabozantinib in combination with atezolizumab in patients with mCRPCПодробнее

Dr. Agarwal on the Safety of Cabozantinib/Atezolizumab in mCRPCПодробнее

Nivolumab Plus Cabozantinib for Patients With Non-Clear Cell Renal Cell CarcinomaПодробнее

Cab + atezo: a new treatment for naïve advanced ccRCCПодробнее

CABATEN/GETNE-T1914: cabozantinib plus atezolizumab in adrenocortical carcinomaПодробнее

Clinical activity of cabozantinib in patients with RCC with brain metastasesПодробнее

COSMIC-021, Cabozantinib in Combination with AtezolizumabПодробнее

Final analysis of the ATLANTIS cabozantinib comparisonПодробнее

Dr. Pal on the Safety Profile of Cabozantinib/Atezolizumab in Advanced RCCПодробнее

Cabozantinib Plus Atezolizumab as First-Line Therapy for Advanced Renal Cell CarcinomaПодробнее

Dr. Pal on the Rationale for Adding Cabozantinib to Atezolizumab in Prostate CancerПодробнее

Cabozantinib as Immune Modulatory Therapy for Advanced RCCПодробнее

Cabozantinib Safety with Anticoagulants in Patients with Renal Cell CarcinomaПодробнее

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinibПодробнее

Cabozantinib Plus Atezolizumab for Non-Clear Cell Renal Cell CarcinomaПодробнее

Neoadjuvant cabozantinib in patients with locally advanced non-metastatic ccRCCПодробнее

Dr. Agarwal on Data With Cabozantinib/Atezolizumab in mCRPCПодробнее

Telaglenastat Plus Cabozantinib for Advanced Renal Cell CarcinomaПодробнее